{{roughtranslation}}
在药物学中，一个'''抗靶标'''可以是一个[[受体|受体]]，[[酶|酶]]，或者其它[[生物靶标|生物靶标]]，当其和药物作用时会引起不希望的[[不良反應_(醫學)|不良反应]]（[[副反应|副反应]]）。对于药物研发公司来说，在药物设计和开发过程中确保新药不和大量的被意外发现的抗靶标产生显著活性是至关重要的。<ref>{{cite journal|title=GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects|pages=876–889|issn=1439-4227|journal=Chembiochem: A European Journal of Chemical Biology|volume=6|issue=5|date=2005-5|doi=10.1002/cbic.200400369|url=https://www.ncbi.nlm.nih.gov/pubmed/15791686|accessdate=2019-02-12|author=Thomas Klabunde, Andreas Evers|pmid=15791686|archive-date=2016-06-10|archive-url=https://web.archive.org/web/20160610164209/http://www.ncbi.nlm.nih.gov/pubmed/15791686|dead-url=no}}</ref><ref>{{cite journal|title=Physicochemical drug properties associated with in vivo toxicological outcomes: a review|pages=921–931|issn=1744-7607|journal=Expert Opinion on Drug Metabolism & Toxicology|volume=5|issue=8|date=2009-8|doi=10.1517/17425250903042318|url=https://www.ncbi.nlm.nih.gov/pubmed/19519283|accessdate=2019-02-12|author=David A. Price, Julian Blagg, Lyn Jones, Nigel Greene, Travis Wager|pmid=19519283|archive-date=2014-11-03|archive-url=https://web.archive.org/web/20141103050136/http://www.ncbi.nlm.nih.gov/pubmed/19519283|dead-url=no}}</ref> 


最知名和最显著的抗靶标分别是[[hERG|hERG]]通道和[[5-HT2B|5-HT<sub>2B</sub>]] 受体，会在小范围但不可预知比例的用药人身上分别引发心脏功能的长期问题——[[QT间期延长综合症|QT间期延长综合症]]和[[心肌纤维化|心肌纤维化]]。这些靶标的发现是由于某些上市药物高频率的特有[[不良反應_(醫學)|不良反应]]；一些具有显著hERG活性的老药依然被警示使用中，大部分被发现是强烈的 5-HT<sub>2B</sub>激动剂的药物不得不从市场退市。因此，任何先导化合物如果在初期的药物筛选中显示出和这些靶标有较高的亲和力，几乎都会被终止开发。
<ref>{{cite journal|title=Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview|pages=263–286|issn=0114-5916|journal=Drug Safety|volume=25|issue=4|date=2002|doi=10.2165/00002018-200225040-00004|url=https://www.ncbi.nlm.nih.gov/pubmed/11994029|accessdate=2019-02-12|author=Fabrizio De Ponti, Elisabetta Poluzzi, Andrea Cavalli, Maurizio Recanatini, Nicola Montanaro|pmid=11994029|archive-date=2015-01-02|archive-url=https://web.archive.org/web/20150102131221/http://www.ncbi.nlm.nih.gov/pubmed/11994029|dead-url=no}}</ref><ref>{{cite journal|title=QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development|pages=133–166|issn=0198-6325|journal=Medicinal Research Reviews|volume=25|issue=2|date=2005-3|doi=10.1002/med.20019|url=https://www.ncbi.nlm.nih.gov/pubmed/15389727|accessdate=2019-02-12|author=Maurizio Recanatini, Elisabetta Poluzzi, Matteo Masetti, Andrea Cavalli, Fabrizio De Ponti|pmid=15389727|archive-date=2015-11-28|archive-url=https://web.archive.org/web/20151128020828/http://www.ncbi.nlm.nih.gov/pubmed/15389727|dead-url=no}}</ref><ref>{{cite journal|title=The hERG K+ channel: target and antitarget strategies in drug development|pages=181–195|issn=1043-6618|journal=Pharmacological Research|volume=57|issue=3|date=2008-3|doi=10.1016/j.phrs.2008.01.009|url=https://www.ncbi.nlm.nih.gov/pubmed/18329284|accessdate=2019-02-12|author=Emanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, Fabrizio De Ponti|pmid=18329284|archive-date=2014-11-03|archive-url=https://web.archive.org/web/20141103045845/http://www.ncbi.nlm.nih.gov/pubmed/18329284|dead-url=no}}</ref><ref>{{cite journal|title=hERG-related drug toxicity and models for predicting hERG liability and QT prolongation|pages=1005–1021|issn=1744-7607|journal=Expert Opinion on Drug Metabolism & Toxicology|volume=5|issue=9|date=2009-9|doi=10.1517/17425250903055070|url=https://www.ncbi.nlm.nih.gov/pubmed/19572824|accessdate=2019-02-12|author=Emanuel Raschi, Luisa Ceccarini, Fabrizio De Ponti, Maurizio Recanatini|pmid=19572824|archive-date=2014-11-03|archive-url=https://web.archive.org/web/20141103050912/http://www.ncbi.nlm.nih.gov/pubmed/19572824|dead-url=no}}</ref><ref>{{cite journal|title=Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment|pages=710–722|issn=1521-0111|journal=Molecular Pharmacology|volume=76|issue=4|date=2009-10|doi=10.1124/mol.109.058057|url=https://www.ncbi.nlm.nih.gov/pubmed/19570945|accessdate=2019-02-12|author=Xi-Ping Huang, Vincent Setola, Prem N. Yadav, John A. Allen, Sarah C. Rogan, Bonnie J. Hanson, Chetana Revankar, Matt Robers, Chris Doucette, Bryan L. Roth|pmid=19570945|pmc=PMC2769050|archive-date=2017-07-12|archive-url=https://web.archive.org/web/20170712183937/https://www.ncbi.nlm.nih.gov/pubmed/19570945|dead-url=no}}</ref><ref>{{cite journal|title=Drug-induced fibrotic valvular heart disease|pages=577–585|issn=1474-547X|journal=Lancet (London, England)|volume=374|issue=9689|date=2009-08-15|doi=10.1016/S0140-6736(09)60252-X|url=https://www.ncbi.nlm.nih.gov/pubmed/19683643|accessdate=2019-02-12|author=Sanjeev Bhattacharyya, Anthony H. Schapira, Dimitri P. Mikhailidis, Joseph Davar|pmid=19683643|archive-date=2015-09-19|archive-url=https://web.archive.org/web/20150919000248/http://www.ncbi.nlm.nih.gov/pubmed/19683643|dead-url=no}}</ref>

==参考文献==
{{reflist}}
<!--In [[pharmacology|pharmacology]], an '''antitarget''' is a [[receptor_(biochemistry)|receptor]], [[enzyme|enzyme]], or other [[biological_target|biological target]] that, when affected by a drug, causes undesirable [[adverse_effect|side-effect]]s. During [[drug_design|drug design]] and [[drug_development|development]], it is important for pharmaceutical companies to ensure that new drugs do not show significant activity at any of a range of antitargets, most of which are discovered largely by chance.<ref>{{cite journal|title=GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects|pages=876–889|issn=1439-4227|journal=Chembiochem: A European Journal of Chemical Biology|volume=6|issue=5|date=2005-5|doi=10.1002/cbic.200400369|url=https://www.ncbi.nlm.nih.gov/pubmed/15791686|accessdate=2019-02-12|author=Thomas Klabunde, Andreas Evers|pmid=15791686}}</ref><ref>{{cite journal|title=Physicochemical drug properties associated with in vivo toxicological outcomes: a review|pages=921–931|issn=1744-7607|journal=Expert Opinion on Drug Metabolism & Toxicology|volume=5|issue=8|date=2009-8|doi=10.1517/17425250903042318|url=https://www.ncbi.nlm.nih.gov/pubmed/19519283|accessdate=2019-02-12|author=David A. Price, Julian Blagg, Lyn Jones, Nigel Greene, Travis Wager|pmid=19519283}}</ref> 

Among the best-known and most significant antitargets are the [[hERG|hERG]] channel and the [[5-HT2B_receptor|5-HT<sub>2B</sub> receptor]], both of which causing long-term problems with heart function that can prove fatal ([[long_QT_syndrome|long QT syndrome]] and [[cardiac_fibrosis|cardiac fibrosis]], respectively), in a small but unpredictable proportion of users. Both of these targets were discovered as a result of high levels of distinctive side-effects during the marketing of certain medicines, and, while some older drugs with significant hERG activity are still used with caution, most drugs that have been found to be strong 5-HT<sub>2B</sub> agonists were withdrawn from the market, and any new compound will almost always be discontinued from further development if initial screening shows high affinity for these targets.<ref>{{cite journal|title=Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview|pages=263–286|issn=0114-5916|journal=Drug Safety|volume=25|issue=4|date=2002|doi=10.2165/00002018-200225040-00004|url=https://www.ncbi.nlm.nih.gov/pubmed/11994029|accessdate=2019-02-12|author=Fabrizio De Ponti, Elisabetta Poluzzi, Andrea Cavalli, Maurizio Recanatini, Nicola Montanaro|pmid=11994029}}</ref><ref>{{cite journal|title=QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development|pages=133–166|issn=0198-6325|journal=Medicinal Research Reviews|volume=25|issue=2|date=2005-3|doi=10.1002/med.20019|url=https://www.ncbi.nlm.nih.gov/pubmed/15389727|accessdate=2019-02-12|author=Maurizio Recanatini, Elisabetta Poluzzi, Matteo Masetti, Andrea Cavalli, Fabrizio De Ponti|pmid=15389727}}</ref><ref>{{cite journal|title=The hERG K+ channel: target and antitarget strategies in drug development|pages=181–195|issn=1043-6618|journal=Pharmacological Research|volume=57|issue=3|date=2008-3|doi=10.1016/j.phrs.2008.01.009|url=https://www.ncbi.nlm.nih.gov/pubmed/18329284|accessdate=2019-02-12|author=Emanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, Fabrizio De Ponti|pmid=18329284}}</ref><ref>{{cite journal|title=hERG-related drug toxicity and models for predicting hERG liability and QT prolongation|pages=1005–1021|issn=1744-7607|journal=Expert Opinion on Drug Metabolism & Toxicology|volume=5|issue=9|date=2009-9|doi=10.1517/17425250903055070|url=https://www.ncbi.nlm.nih.gov/pubmed/19572824|accessdate=2019-02-12|author=Emanuel Raschi, Luisa Ceccarini, Fabrizio De Ponti, Maurizio Recanatini|pmid=19572824}}</ref><ref>{{cite journal|title=Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment|pages=710–722|issn=1521-0111|journal=Molecular Pharmacology|volume=76|issue=4|date=2009-10|doi=10.1124/mol.109.058057|url=https://www.ncbi.nlm.nih.gov/pubmed/19570945|accessdate=2019-02-12|author=Xi-Ping Huang, Vincent Setola, Prem N. Yadav, John A. Allen, Sarah C. Rogan, Bonnie J. Hanson, Chetana Revankar, Matt Robers, Chris Doucette, Bryan L. Roth|pmid=19570945|pmc=PMC2769050}}</ref><ref>{{cite journal|title=Drug-induced fibrotic valvular heart disease|pages=577–585|issn=1474-547X|journal=Lancet (London, England)|volume=374|issue=9689|date=2009-08-15|doi=10.1016/S0140-6736(09)60252-X|url=https://www.ncbi.nlm.nih.gov/pubmed/19683643|accessdate=2019-02-12|author=Sanjeev Bhattacharyya, Anthony H. Schapira, Dimitri P. Mikhailidis, Joseph Davar|pmid=19683643}}</ref>

-->
[[Category:制药工业|Category:制药工业]]
[[Category:药物化学|Category:药物化学]]
[[Category:药物发现|Category:药物发现]]